Repromeda contributes to the latest advancements in the field of assisted reproduction and genetic testing. We are proud that our experts – the clinic director, MUDr. Kateřina Veselá, Ph.D., the director of the genetics laboratory, Mgr. David Kubíček, Ph.D., and the director of research and development, Mgr. Miroslav Horňák, Ph.D. – are co-authors of a paper presented at the Assisted Reproduction Conference in Indian Wells, California, in 2024
Mosaicism, detected through preimplantation genetic testing (PGT-A), is a topic that is receiving increasing attention due to its impact on implantation and pregnancy development. This phenomenon involves the presence of both euploid and aneuploid cells within an embryo and can affect pregnancy outcomes, making it an important aspect of assisted reproduction. While some embryos with detected mosaicism can lead to healthy pregnancies, others may cause complications. Our collaboration on this study provides new insights into the clinical management of embryos with mosaicism and their possible persistence during pregnancy, including potential impacts on fetal development. This research can significantly contribute to decision-making processes in infertility treatment and the further development of standards for preimplantation and prenatal testing.
Data from the international registry, to which Repromeda also contributes, helped to create the basis for recommendations regarding monitoring pregnancies following mosaic embryo transfers. The publication mentions that combining a 24-chromosome NIPT test and amniocentesis with microarray analysis represents an effective strategy to ensure the safety of pregnancies after mosaic embryo transfer.
Comments